Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen : CEO Offers Career Advice to Summer Interns (And the Rest of Us)

07/22/2021 | 10:58am EDT

Amgen CEO Bob Bradway addressed a virtual gathering of more than 150 Amgen summer interns on July 13, sharing his thoughts on our company, the future of biopharmaceutical innovation, and what it takes to have a successful career.

Reflecting on the company's founding 41 years ago, Bradway said that Amgen was 'dreaming big then and is dreaming big now.' He shared his optimism that incredible advances in science and technology will enable Amgen and the rest of the biopharmaceutical industry to meet the health needs of a rapidly aging and increasingly wealthy global population.

'The industry's ability to develop several safe and effective COVID vaccines in under a year shows definitively that we have entered the biocentury,' Bradway said. 'This is a very exciting time that will be characterized by profound innovation.'

In terms of career advice, Bradway offered these five tips:

  • Do work that matters to you - Bradway called himself the 'luckiest person in the world' because he has been able to line up his life-long passion for biology with his career choices - first as an investment banker focused on the biotech industry at Morgan Stanley and now as a leader at Amgen. When asked how he starts his day, he said his focus is always on how Amgen can serve more patients and that the company's mission provides a critical 'North Star' that guides and motivates the entire company.
  • Work alongside great people - Bradway called Amgen's people our 'secret sauce' and said that a big part of his job is making sure that we have the right people in place who are doing the right work. He added that Amgen's social architecture has been a powerful tool to align the company's more than 24,000 staff around a set of common beliefs and behaviors.
  • Work for a well-resourced company - Doing great things often requires great resources, as evidenced by the billions of dollars Amgen spends every year on research and development and our ability to reach patients in some 100 countries. Bradway encouraged the interns to work for a company that has the resources needed to succeed.
  • Look to fill the void - Bradway encouraged the interns to find the gaps that inevitably exist at a company and 'fill the void.' After spending 20 years at Morgan Stanley, for example, he joined Amgen, thinking that his experience in finance and strategy would help to fill a gap at the company, which was then exploring how best to achieve its next phase of growth. Similarly, he said, young people who have been comfortable with technology their entire lives can help a company like Amgen meet the need to strengthen its digital capabilities.
  • Be impatient - Bradway said that, as a CEO, 'the clock is always ticking' and there is precious little time to truly make an impact. He encouraged the interns to aim high early in their careers, rather than waiting until later on to try to do something great. 'There are a lot of big, urgent challenges facing the world,' he said. 'Go out and make a difference as soon as you can.'

Bradway's advice resonated with Kartikeya Agarwal, a rising senior at Claremont McKenna College, who is an intern in our Finance organization.

'Two things that stood out to me the most were Bob's commitment to Amgen's mission of serving patients, confirming that I made the right decision by interning here, and his excitement for the future of the biotech industry,' Kartikeya says. 'After hearing him talk about the rapid changes and staggering breakthroughs that we will witness in the near future, it is not surprising that Amgen invests so much time and effort into cultivating interns who would be equipped to take on these challenges and achieve results. So for me, the session was eye-opening and Bob helped me visualize the bigger picture behind every number I input into a spreadsheet.'

BTW, did you know that Bob is active on LinkedIn? Click here to follow him.

Disclaimer

Amgen Inc. published this content on 22 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 July 2021 14:57:10 UTC.


ę Publicnow 2021
All news about AMGEN INC.
09/19MIRATI THERAPEUTICS : drug combination shrinks tumors in 39% of colon cancer pat..
RE
09/17AMGEN : Celebrates 20 Years of Aranesp« (darbepoetin alfa) as a Treatment for Pa..
PU
09/16AMGEN : Diversity, Inclusion and Belonging at Amgen – A Progress Report
PU
09/16AMGEN : Enters Collaboration With Boehringer Ingelheim to Study Drug Combination..
MT
09/16AMGEN : Conference Call from ESMO Presentation
PU
09/16AMGEN : Says Colorectal Cancer Drug Combination Safe and Effective in Trial
MT
09/16AMGEN : LUMAKRAS™ (Sotorasib) Combined With Vectibix« (Panitumumab) Showed..
PR
09/16Amgen Inc. Announces the First Combination Study Results from the Phase 1B/2 ..
CI
09/15China's biotech sector comes of age with big licensing deals, global ambition..
RE
09/14AMGEN : And The Lundquist Institute Announce That Diadem Therapeuctics Will Rece..
PR
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2021 26 045 M - -
Net income 2021 6 027 M - -
Net Debt 2021 22 255 M - -
P/E ratio 2021 21,7x
Yield 2021 3,16%
Capitalization 125 B 125 B -
EV / Sales 2021 5,64x
EV / Sales 2022 5,30x
Nbr of Employees 24 300
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | AMGN | US0311621009 | MarketScreener
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 219,38 $
Average target price 245,81 $
Spread / Average Target 12,0%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.-4.58%124 575
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.19.23%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604